Population-wide impacts of aspirin, statins, and metformin use on prostate cancer incidence and mortality

We evaluated the association between aspirin, statins, and metformin use and prostate cancer (PC) incidence and mortality using a large population-based dataset. 388,760 men who participated in national health screening program in Korea during 2002–2003 were observed from 2004 to 2013. Hazard ratios...

Full description

Saved in:
Bibliographic Details
Published inScientific reports Vol. 11; no. 1; pp. 16171 - 9
Main Authors Koo, Hye Yeon, Jeong, Su-Min, Cho, Mi Hee, Chun, Sohyun, Shin, Dong Wook, Park, Jinsung
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 09.08.2021
Nature Publishing Group
Nature Portfolio
Subjects
692/308/174
692/699/67
692/699/67/2195
692/699/67/2324
692/699/67/589
692/699/67/589/466
Antidiabetics
Aspirin
Diabetes mellitus
Drug dosages
Humanities and Social Sciences
Medical screening
Metformin
Mortality
multidisciplinary
Prostate cancer
Science
Science (multidisciplinary)
Statins
Online AccessGet full text

Cover

Abstract We evaluated the association between aspirin, statins, and metformin use and prostate cancer (PC) incidence and mortality using a large population-based dataset. 388,760 men who participated in national health screening program in Korea during 2002–2003 were observed from 2004 to 2013. Hazard ratios of aspirin, statins, and metformin use for PC incidence and PC mortality were calculated with adjustment for simultaneous drug use. Cumulative use of each drug was inserted as time-dependent variable with 2-year time windows. Aspirin use ≥ 1.5 year (per 2-year) was associated with borderline decrease in PC mortality when compared to non-users (adjusted hazard ratio [aHR] 0.71, 95% confidence interval [CI] 0.50–1.02). Statins use was not associated with either PC incidence or PC mortality. Metformin ever-use was associated with decreased PC incidence compared with non-diabetics (aHR 0.86, 95% CI 0.77–0.96). Diabetics who were not using metformin or using low cumulative doses had higher PC mortality than non-diabetics (aHR 2.01, 95% CI 1.44–2.81, and aHR 1.70, 95% CI 1.07–2.69, respectively). However, subjects with higher cumulative doses of metformin did not show increased PC mortality. In conclusion, metformin use was associated with lower PC incidence. Use of aspirin and that of metformin among diabetic patients were associated with lower PC mortality.
AbstractList We evaluated the association between aspirin, statins, and metformin use and prostate cancer (PC) incidence and mortality using a large population-based dataset. 388,760 men who participated in national health screening program in Korea during 2002–2003 were observed from 2004 to 2013. Hazard ratios of aspirin, statins, and metformin use for PC incidence and PC mortality were calculated with adjustment for simultaneous drug use. Cumulative use of each drug was inserted as time-dependent variable with 2-year time windows. Aspirin use ≥ 1.5 year (per 2-year) was associated with borderline decrease in PC mortality when compared to non-users (adjusted hazard ratio [aHR] 0.71, 95% confidence interval [CI] 0.50–1.02). Statins use was not associated with either PC incidence or PC mortality. Metformin ever-use was associated with decreased PC incidence compared with non-diabetics (aHR 0.86, 95% CI 0.77–0.96). Diabetics who were not using metformin or using low cumulative doses had higher PC mortality than non-diabetics (aHR 2.01, 95% CI 1.44–2.81, and aHR 1.70, 95% CI 1.07–2.69, respectively). However, subjects with higher cumulative doses of metformin did not show increased PC mortality. In conclusion, metformin use was associated with lower PC incidence. Use of aspirin and that of metformin among diabetic patients were associated with lower PC mortality.
We evaluated the association between aspirin, statins, and metformin use and prostate cancer (PC) incidence and mortality using a large population-based dataset. 388,760 men who participated in national health screening program in Korea during 2002-2003 were observed from 2004 to 2013. Hazard ratios of aspirin, statins, and metformin use for PC incidence and PC mortality were calculated with adjustment for simultaneous drug use. Cumulative use of each drug was inserted as time-dependent variable with 2-year time windows. Aspirin use ≥ 1.5 year (per 2-year) was associated with borderline decrease in PC mortality when compared to non-users (adjusted hazard ratio [aHR] 0.71, 95% confidence interval [CI] 0.50-1.02). Statins use was not associated with either PC incidence or PC mortality. Metformin ever-use was associated with decreased PC incidence compared with non-diabetics (aHR 0.86, 95% CI 0.77-0.96). Diabetics who were not using metformin or using low cumulative doses had higher PC mortality than non-diabetics (aHR 2.01, 95% CI 1.44-2.81, and aHR 1.70, 95% CI 1.07-2.69, respectively). However, subjects with higher cumulative doses of metformin did not show increased PC mortality. In conclusion, metformin use was associated with lower PC incidence. Use of aspirin and that of metformin among diabetic patients were associated with lower PC mortality.We evaluated the association between aspirin, statins, and metformin use and prostate cancer (PC) incidence and mortality using a large population-based dataset. 388,760 men who participated in national health screening program in Korea during 2002-2003 were observed from 2004 to 2013. Hazard ratios of aspirin, statins, and metformin use for PC incidence and PC mortality were calculated with adjustment for simultaneous drug use. Cumulative use of each drug was inserted as time-dependent variable with 2-year time windows. Aspirin use ≥ 1.5 year (per 2-year) was associated with borderline decrease in PC mortality when compared to non-users (adjusted hazard ratio [aHR] 0.71, 95% confidence interval [CI] 0.50-1.02). Statins use was not associated with either PC incidence or PC mortality. Metformin ever-use was associated with decreased PC incidence compared with non-diabetics (aHR 0.86, 95% CI 0.77-0.96). Diabetics who were not using metformin or using low cumulative doses had higher PC mortality than non-diabetics (aHR 2.01, 95% CI 1.44-2.81, and aHR 1.70, 95% CI 1.07-2.69, respectively). However, subjects with higher cumulative doses of metformin did not show increased PC mortality. In conclusion, metformin use was associated with lower PC incidence. Use of aspirin and that of metformin among diabetic patients were associated with lower PC mortality.
We evaluated the association between aspirin, statins, and metformin use and prostate cancer (PC) incidence and mortality using a large population-based dataset. 388,760 men who participated in national health screening program in Korea during 2002–2003 were observed from 2004 to 2013. Hazard ratios of aspirin, statins, and metformin use for PC incidence and PC mortality were calculated with adjustment for simultaneous drug use. Cumulative use of each drug was inserted as time-dependent variable with 2-year time windows. Aspirin use ≥ 1.5 year (per 2-year) was associated with borderline decrease in PC mortality when compared to non-users (adjusted hazard ratio [aHR] 0.71, 95% confidence interval [CI] 0.50–1.02). Statins use was not associated with either PC incidence or PC mortality. Metformin ever-use was associated with decreased PC incidence compared with non-diabetics (aHR 0.86, 95% CI 0.77–0.96). Diabetics who were not using metformin or using low cumulative doses had higher PC mortality than non-diabetics (aHR 2.01, 95% CI 1.44–2.81, and aHR 1.70, 95% CI 1.07–2.69, respectively). However, subjects with higher cumulative doses of metformin did not show increased PC mortality. In conclusion, metformin use was associated with lower PC incidence. Use of aspirin and that of metformin among diabetic patients were associated with lower PC mortality.
Abstract We evaluated the association between aspirin, statins, and metformin use and prostate cancer (PC) incidence and mortality using a large population-based dataset. 388,760 men who participated in national health screening program in Korea during 2002–2003 were observed from 2004 to 2013. Hazard ratios of aspirin, statins, and metformin use for PC incidence and PC mortality were calculated with adjustment for simultaneous drug use. Cumulative use of each drug was inserted as time-dependent variable with 2-year time windows. Aspirin use ≥ 1.5 year (per 2-year) was associated with borderline decrease in PC mortality when compared to non-users (adjusted hazard ratio [aHR] 0.71, 95% confidence interval [CI] 0.50–1.02). Statins use was not associated with either PC incidence or PC mortality. Metformin ever-use was associated with decreased PC incidence compared with non-diabetics (aHR 0.86, 95% CI 0.77–0.96). Diabetics who were not using metformin or using low cumulative doses had higher PC mortality than non-diabetics (aHR 2.01, 95% CI 1.44–2.81, and aHR 1.70, 95% CI 1.07–2.69, respectively). However, subjects with higher cumulative doses of metformin did not show increased PC mortality. In conclusion, metformin use was associated with lower PC incidence. Use of aspirin and that of metformin among diabetic patients were associated with lower PC mortality.
ArticleNumber 16171
Author Chun, Sohyun
Jeong, Su-Min
Koo, Hye Yeon
Shin, Dong Wook
Cho, Mi Hee
Park, Jinsung
Author_xml – sequence: 1
  givenname: Hye Yeon
  surname: Koo
  fullname: Koo, Hye Yeon
  organization: Health Promotion Center, CHA Bundang Medical Center
– sequence: 2
  givenname: Su-Min
  surname: Jeong
  fullname: Jeong, Su-Min
  organization: Department of Family Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine
– sequence: 3
  givenname: Mi Hee
  surname: Cho
  fullname: Cho, Mi Hee
  organization: Samsung C&T Medical Clinic, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine
– sequence: 4
  givenname: Sohyun
  surname: Chun
  fullname: Chun, Sohyun
  organization: Department of Family Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, International Healthcare Center, Samsung Medical Center
– sequence: 5
  givenname: Dong Wook
  surname: Shin
  fullname: Shin, Dong Wook
  email: dwshin.md@gmail.com
  organization: Department of Family Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Supportive Care Center, Samsung Comprehensive Cancer Center, Department of Digital Health, SAIHST, Sungkyunkwan University, Department of Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University
– sequence: 6
  givenname: Jinsung
  surname: Park
  fullname: Park, Jinsung
  organization: Department of Urology, Uijeongbu Eulji Medical Center, Eulji University
BookMark eNp9kk1vFSEUhiemxtbaP-CKxI2Ljg5fA2xMTONHkya60DU5A8yVmxkYgdH038u9U6Ptomwg8LwvcM77vDkJMbimeYm7N7ij8m1mmCvZdgS3iouetfRJc0Y6xltCCTn5b33aXOS87-rgRDGsnjWnlFFBuWRnjf8al3WC4mNof3vrkJ8XMCWjOCLIi08-XKJcKhDyJYJg0ezKGNPsA1qzQzGgJcUD4JCBYFxCPphqVJcbHlOByZfbF83TEabsLu7m8-b7xw_frj63N18-XV-9v2kNx6K0PcVCKTqwnhkQasAAYGknBmwkAcGGYejBcjGyrpfUDspwgrGgzghnLRnpeXO9-doIe70kP0O61RG8Pm7EtNOQijeT084oObCOKucYI9ICI1b0FjM6Sgzq4PVu81rWYXbWuFASTPdM758E_0Pv4i8tKSdS9dXg9Z1Bij9Xl4uefTZumiC4uGZNeF_bIpgQFX31AN3HNYVaqkpxxVnHCKmU3ChTq56TG7Xx5di-er-fNO70IR56i4eu8dDHeGhapeSB9O8_HhXRTZQrHHYu_XvVI6o_GV7O_w
CitedBy_id crossref_primary_10_3390_cancers14143500
crossref_primary_10_1038_s41391_024_00871_7
crossref_primary_10_1007_s12672_025_01829_4
crossref_primary_10_1155_2024_2699572
crossref_primary_10_1016_j_ejca_2023_113348
crossref_primary_10_3390_cancers14051211
crossref_primary_10_1038_s41598_022_05793_9
crossref_primary_10_3390_ijms26062720
crossref_primary_10_1007_s00228_023_03556_7
Cites_doi 10.1371/journal.pone.0033411
10.1200/JCO.2016.71.8981
10.1002/pros.23019
10.1002/ijc.32083
10.1016/j.euf.2016.05.004
10.14309/00000434-201806000-00015
10.1038/s41598-020-70624-8
10.1002/dmrr.2582
10.1038/nrclinonc.2013.169
10.1016/j.canep.2013.10.010
10.1038/bjc.2015.259
10.1002/cncr.24890
10.1111/j.1742-1241.2007.01630.x
10.1016/j.ijcard.2016.09.075
10.1016/j.eururo.2012.12.004
10.7326/M17-3085
10.1016/j.ejca.2014.08.007
10.4143/crt.2015.212
10.1158/0008-5472.CAN-10-2470
10.1158/1055-9965.EPI-16-1027
10.1158/1940-6207.CAPR-15-0141
10.1016/j.ijrobp.2012.02.050
10.1007/s10552-005-3301-z
10.1016/j.eururo.2014.04.027
10.1001/jamaoncol.2015.6396
10.1161/JAHA.115.002320
10.1158/1055-9965.EPI-13-0196
10.1002/pros.23138
10.1371/journal.pone.0116327
10.2147/CLEP.S113211
10.1038/nrc1751
10.1016/j.euo.2018.07.002
10.1158/1055-9965.EPI-18-0965
10.3322/caac.21492
10.1158/1940-6207.CAPR-17-0033
10.2165/11318440-000000000-00000
10.1371/journal.pone.0152402
10.4103/1008-682X.168687
10.1002/ijc.31295
10.1200/JCO.2012.46.7043
10.1016/0021-9681(87)90171-8
10.4143/crt.2018.143
10.1093/annonc/mdt428
10.1038/pcan.2016.65
10.1161/CIRCULATIONAHA.117.032321
10.1093/jnci/djj499
10.1186/s40064-016-3233-y
10.4111/icu.2017.58.6.434
10.1038/s41391-020-0207-5
10.1158/1055-9965.EPI-19-0464
10.4143/crt.2020.206
ContentType Journal Article
Copyright The Author(s) 2021
The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2021. The Author(s).
Copyright_xml – notice: The Author(s) 2021
– notice: The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2021. The Author(s).
DBID C6C
AAYXX
CITATION
3V.
7X7
7XB
88A
88E
88I
8FE
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M2P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.1038/s41598-021-95764-3
DatabaseName Springer Nature OA Free Journals
CrossRef
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central Korea
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Health & Medical Collection (Alumni)
Medical Database
Science Database (ProQuest)
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ (Directory of Open Access Journals)
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic

Publicly Available Content Database

CrossRef
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2045-2322
EndPage 9
ExternalDocumentID oai_doaj_org_article_ec98b4039ee4428da42d76d143f81a9f
PMC8352896
10_1038_s41598_021_95764_3
GroupedDBID 0R~
3V.
4.4
53G
5VS
7X7
88A
88E
88I
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AAKDD
ABDBF
ABUWG
ACGFS
ACSMW
ACUHS
ADBBV
ADRAZ
AENEX
AEUYN
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
DWQXO
EBD
EBLON
EBS
ESX
FYUFA
GNUQQ
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
KQ8
LK8
M0L
M1P
M2P
M48
M7P
M~E
NAO
OK1
PIMPY
PQQKQ
PROAC
PSQYO
RNT
RNTTT
RPM
SNYQT
UKHRP
AASML
AAYXX
AFPKN
CITATION
PHGZM
PHGZT
7XB
8FK
AARCD
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
Q9U
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c517t-6317993b464ca79b1aaad307b1c82a74bbb6ad57f40683db9c521173ec7edd2f3
IEDL.DBID M48
ISSN 2045-2322
IngestDate Wed Aug 27 01:30:16 EDT 2025
Thu Aug 21 18:14:35 EDT 2025
Fri Jul 11 06:20:50 EDT 2025
Wed Aug 13 11:11:33 EDT 2025
Thu Apr 24 23:05:33 EDT 2025
Tue Jul 01 03:49:05 EDT 2025
Fri Feb 21 02:39:02 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c517t-6317993b464ca79b1aaad307b1c82a74bbb6ad57f40683db9c521173ec7edd2f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1038/s41598-021-95764-3
PMID 34373584
PQID 2559540422
PQPubID 2041939
PageCount 9
ParticipantIDs doaj_primary_oai_doaj_org_article_ec98b4039ee4428da42d76d143f81a9f
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8352896
proquest_miscellaneous_2560057477
proquest_journals_2559540422
crossref_citationtrail_10_1038_s41598_021_95764_3
crossref_primary_10_1038_s41598_021_95764_3
springer_journals_10_1038_s41598_021_95764_3
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-08-09
PublicationDateYYYYMMDD 2021-08-09
PublicationDate_xml – month: 08
  year: 2021
  text: 2021-08-09
  day: 09
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle Scientific reports
PublicationTitleAbbrev Sci Rep
PublicationYear 2021
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Noto, Goto, Tsujimoto, Noda (CR8) 2012; 7
Tsoi, Ho, Chan, Sung (CR5) 2019; 145
Keskivali, Kujala, Visakorpi, Tammela, Murtola (CR42) 2016; 76
Hong (CR3) 2020; 52
Kim, Chang, Kim, Banerjee, Park (CR29) 2018; 113
Platz (CR16) 2006; 98
Cai (CR50) 2015; 31
CR33
Cao (CR6) 2016; 2
Langley (CR39) 2013; 7
Smiechowski (CR30) 2013; 22
Kumar (CR45) 2020; 23
Christensen, Rungby, Thomsen (CR25) 2016; 8
Margel (CR15) 2013; 31
Feng (CR48) 2015; 8
Zaorsky, Buyyounouski, Li, Horwitz (CR37) 2012; 84
Righolt, Bisewski, Mahmud (CR22) 2019; 28
Zanders (CR31) 2015; 113
Bray (CR1) 2018; 68
Demierre, Higgins, Gruber, Hawk, Lippman (CR7) 2005; 5
Jespersen, Nørgaard, Friis, Skriver, Borre (CR17) 2014; 38
Herlitz, Tóth, Naesdal (CR26) 2010; 10
Jung, Won, Kong, Lee (CR2) 2018; 50
Lubik (CR51) 2011; 71
Dawe (CR43) 2018; 143
Downer (CR10) 2019; 2
Cramer, Benedict, Muszbek, Keskinaslan, Khan (CR27) 2008; 62
Hurwitz (CR36) 2019; 28
Kantor (CR46) 2015; 75
Lloyd, Slivova, Valachovicova, Sliva (CR41) 2003; 23
Choe, Correa, Jani, Liauw (CR38) 2010; 116
Chen, Eurich, Majumdar, Johnson (CR21) 2017; 20
Tan (CR44) 2017; 19
Skriver (CR11) 2019; 170
Zhou (CR20) 2017; 10
Smith (CR9) 2017; 26
Murtola (CR19) 2017; 3
Gronich, Rennert (CR4) 2013; 10
Choi (CR35) 2020; 10
Park, Suh, Shin, Hong, Ahn (CR32) 2016; 48
Lee, Giovannucci, Jeon (CR49) 2016; 5
Yu (CR47) 2014; 9
Preston (CR13) 2014; 66
Larsen (CR18) 2017; 35
Spratt (CR53) 2013; 63
Flahavan, Bennett, Sharp, Barron (CR12) 2014; 25
Banach, Stulc, Dent, Toth (CR28) 2016; 225
Luepker (CR23) 2015; 4
Charlson, Pompei, Ales, MacKenzie (CR34) 1987; 40
Elwood (CR40) 2016; 11
Tseng (CR14) 2014; 50
Bucholz, Rodday, Kolor, Khoury, de Ferranti (CR24) 2018; 137
Chan (CR52) 2005; 16
Ahn (CR54) 2017; 58
J Lee (95764_CR49) 2016; 5
DE Spratt (95764_CR53) 2013; 63
H Ahn (95764_CR54) 2017; 58
C Skriver (95764_CR11) 2019; 170
J Park (95764_CR32) 2016; 48
MK Downer (95764_CR10) 2019; 2
M Banach (95764_CR28) 2016; 225
FP Lloyd Jr (95764_CR41) 2003; 23
Y Cao (95764_CR6) 2016; 2
JA Cramer (95764_CR27) 2008; 62
CG Jespersen (95764_CR17) 2014; 38
RV Luepker (95764_CR23) 2015; 4
J Chan (95764_CR52) 2005; 16
S Hong (95764_CR3) 2020; 52
NG Zaorsky (95764_CR37) 2012; 84
D Margel (95764_CR15) 2013; 31
LM Hurwitz (95764_CR36) 2019; 28
TJ Murtola (95764_CR19) 2017; 3
T Feng (95764_CR48) 2015; 8
MF Demierre (95764_CR7) 2005; 5
J Herlitz (95764_CR26) 2010; 10
KW Jung (95764_CR2) 2018; 50
DE Dawe (95764_CR43) 2018; 143
CK Zhou (95764_CR20) 2017; 10
KS Choe (95764_CR38) 2010; 116
PC Elwood (95764_CR40) 2016; 11
CH Righolt (95764_CR22) 2019; 28
H Noto (95764_CR8) 2012; 7
DH Christensen (95764_CR25) 2016; 8
EM Flahavan (95764_CR12) 2014; 25
MH Kim (95764_CR29) 2018; 113
ME Charlson (95764_CR34) 1987; 40
H Cai (95764_CR50) 2015; 31
F Bray (95764_CR1) 2018; 68
AA Lubik (95764_CR51) 2011; 71
ED Kantor (95764_CR46) 2015; 75
SB Larsen (95764_CR18) 2017; 35
CB Chen (95764_CR21) 2017; 20
P Tan (95764_CR44) 2017; 19
T Keskivali (95764_CR42) 2016; 76
N Gronich (95764_CR4) 2013; 10
KKF Tsoi (95764_CR5) 2019; 145
CH Tseng (95764_CR14) 2014; 50
EM Bucholz (95764_CR24) 2018; 137
CJ Smith (95764_CR9) 2017; 26
B Smiechowski (95764_CR30) 2013; 22
H Yu (95764_CR47) 2014; 9
A Kumar (95764_CR45) 2020; 23
MA Preston (95764_CR13) 2014; 66
EA Platz (95764_CR16) 2006; 98
JS Choi (95764_CR35) 2020; 10
95764_CR33
M Zanders (95764_CR31) 2015; 113
RE Langley (95764_CR39) 2013; 7
References_xml – volume: 7
  start-page: e33411
  year: 2012
  ident: CR8
  article-title: Cancer risk in diabetic patients treated with metformin: A systematic review and meta-analysis
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0033411
– volume: 35
  start-page: 3290
  year: 2017
  end-page: 3297
  ident: CR18
  article-title: Postdiagnosis statin use and mortality in Danish patients with prostate cancer
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2016.71.8981
– volume: 75
  start-page: 1384
  year: 2015
  end-page: 1393
  ident: CR46
  article-title: Statin use and risk of prostate cancer: Results from the Southern Community Cohort Study
  publication-title: Prostate
  doi: 10.1002/pros.23019
– volume: 145
  start-page: 267
  year: 2019
  end-page: 273
  ident: CR5
  article-title: Long-term use of low-dose aspirin for cancer prevention: A 10-year population cohort study in Hong Kong
  publication-title: Int. J. Cancer
  doi: 10.1002/ijc.32083
– volume: 3
  start-page: 212
  year: 2017
  end-page: 220
  ident: CR19
  article-title: Statin use and prostate cancer survival in the Finnish randomized study of screening for prostate cancer
  publication-title: Eur. Urol. Focus
  doi: 10.1016/j.euf.2016.05.004
– volume: 113
  start-page: 845
  year: 2018
  end-page: 854
  ident: CR29
  article-title: Cumulative dose threshold for the chemopreventive effect of aspirin against gastric cancer
  publication-title: Am. J. Gastroenterol.
  doi: 10.14309/00000434-201806000-00015
– volume: 10
  start-page: 13715
  year: 2020
  ident: CR35
  article-title: Recalibration and validation of the Charlson Comorbidity Index in an Asian population: The National Health Insurance Service-National Sample Cohort study
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-020-70624-8
– volume: 31
  start-page: 336
  year: 2015
  end-page: 343
  ident: CR50
  article-title: Diabetes mellitus is associated with elevated risk of mortality amongst patients with prostate cancer: A meta-analysis of 11 cohort studies
  publication-title: Diabetes Metab Res. Rev.
  doi: 10.1002/dmrr.2582
– volume: 10
  start-page: 625
  year: 2013
  end-page: 642
  ident: CR4
  article-title: Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/nrclinonc.2013.169
– volume: 38
  start-page: 42
  year: 2014
  end-page: 47
  ident: CR17
  article-title: Statin use and risk of prostate cancer: A Danish population-based case-control study, 1997–2010
  publication-title: Cancer Epidemiol.
  doi: 10.1016/j.canep.2013.10.010
– volume: 113
  start-page: 403
  year: 2015
  ident: CR31
  article-title: Are metformin, statin and aspirin use still associated with overall mortality among colorectal cancer patients with diabetes if adjusted for one another?
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.2015.259
– volume: 116
  start-page: 1820
  year: 2010
  end-page: 1826
  ident: CR38
  article-title: The use of anticoagulants improves biochemical control of localized prostate cancer treated with radiotherapy
  publication-title: Cancer
  doi: 10.1002/cncr.24890
– volume: 62
  start-page: 76
  year: 2008
  end-page: 87
  ident: CR27
  article-title: The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: A review
  publication-title: Int. J. Clin. Pract.
  doi: 10.1111/j.1742-1241.2007.01630.x
– volume: 225
  start-page: 184
  year: 2016
  end-page: 196
  ident: CR28
  article-title: Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement
  publication-title: Int. J. Cardiol.
  doi: 10.1016/j.ijcard.2016.09.075
– volume: 63
  start-page: 709
  year: 2013
  end-page: 716
  ident: CR53
  article-title: Metformin and prostate cancer: Reduced development of castration-resistant disease and prostate cancer mortality
  publication-title: Eur. Urol.
  doi: 10.1016/j.eururo.2012.12.004
– volume: 170
  start-page: 443
  year: 2019
  end-page: 452
  ident: CR11
  article-title: Use of low-dose aspirin and mortality after prostate cancer diagnosis: A nationwide cohort study
  publication-title: Ann. Intern. Med.
  doi: 10.7326/M17-3085
– volume: 50
  start-page: 2831
  year: 2014
  end-page: 2837
  ident: CR14
  article-title: Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2014.08.007
– volume: 48
  start-page: 899
  year: 2016
  end-page: 906
  ident: CR32
  article-title: Changing patterns of primary treatment in Korean men with prostate cancer over 10 years: A nationwide population based study
  publication-title: Cancer Res. Treat.
  doi: 10.4143/crt.2015.212
– volume: 71
  start-page: 5754
  year: 2011
  end-page: 5764
  ident: CR51
  article-title: Insulin increases de novo steroidogenesis in prostate cancer cells
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-10-2470
– volume: 26
  start-page: 845
  year: 2017
  end-page: 853
  ident: CR9
  article-title: Aspirin use reduces the risk of aggressive prostate cancer and disease recurrence in African–American men
  publication-title: Cancer Epidemiol. Biomarkers Prev.
  doi: 10.1158/1055-9965.EPI-16-1027
– volume: 8
  start-page: 1055
  year: 2015
  end-page: 1060
  ident: CR48
  article-title: Metformin use and risk of prostate cancer: Results from the REDUCE study
  publication-title: Cancer Prev. Res. (Phila.)
  doi: 10.1158/1940-6207.CAPR-15-0141
– volume: 84
  start-page: e13
  year: 2012
  end-page: 17
  ident: CR37
  article-title: Aspirin and statin nonuse associated with early biochemical failure after prostate radiation therapy
  publication-title: Int. J. Radiat. Oncol. Biol. Phys.
  doi: 10.1016/j.ijrobp.2012.02.050
– volume: 16
  start-page: 789
  year: 2005
  end-page: 797
  ident: CR52
  article-title: History of diabetes, clinical features of prostate cancer, and prostate cancer recurrence-data from CaPSURE TM (United States)
  publication-title: Cancer Causes Control
  doi: 10.1007/s10552-005-3301-z
– volume: 66
  start-page: 1012
  year: 2014
  end-page: 1020
  ident: CR13
  article-title: Metformin use and prostate cancer risk
  publication-title: Eur. Urol.
  doi: 10.1016/j.eururo.2014.04.027
– volume: 2
  start-page: 762
  year: 2016
  end-page: 769
  ident: CR6
  article-title: Population-wide impact of long-term use of aspirin and the risk for cancer
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2015.6396
– volume: 4
  start-page: 12
  year: 2015
  ident: CR23
  article-title: Population trends in aspirin use for cardiovascular disease prevention 1980–2009: The Minnesota Heart Survey
  publication-title: J. Am. Heart Assoc.
  doi: 10.1161/JAHA.115.002320
– volume: 22
  start-page: 1877
  year: 2013
  end-page: 1883
  ident: CR30
  article-title: The use of metformin and colorectal cancer incidence in patients with type II diabetes mellitus
  publication-title: Cancer Epidemiol. Biomarkers Prev.
  doi: 10.1158/1055-9965.EPI-13-0196
– volume: 76
  start-page: 469
  year: 2016
  end-page: 478
  ident: CR42
  article-title: Statin use and risk of disease recurrence and death after radical prostatectomy
  publication-title: Prostate
  doi: 10.1002/pros.23138
– volume: 23
  start-page: 1277
  year: 2003
  end-page: 1283
  ident: CR41
  article-title: Aspirin inhibits highly invasive prostate cancer cells
  publication-title: Int. J. Oncol.
– volume: 9
  start-page: e116327
  year: 2014
  ident: CR47
  article-title: Effect of metformin on cancer risk and treatment outcome of prostate cancer: A meta-analysis of epidemiological observational studies
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0116327
– volume: 8
  start-page: 381
  year: 2016
  end-page: 387
  ident: CR25
  article-title: Nationwide trends in glucose-lowering drug use, Denmark, 1999–2014
  publication-title: Clin. Epidemiol.
  doi: 10.2147/CLEP.S113211
– ident: CR33
– volume: 7
  start-page: 297
  year: 2013
  ident: CR39
  article-title: Clinical evidence for the use of aspirin in the treatment of cancer
  publication-title: Ecancermedicalscience
– volume: 5
  start-page: 930
  year: 2005
  end-page: 942
  ident: CR7
  article-title: Statins and cancer prevention
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc1751
– volume: 2
  start-page: 126
  year: 2019
  end-page: 134
  ident: CR10
  article-title: Aspirin use and lethal prostate cancer in the Health Professionals Follow-up Study
  publication-title: Eur. Urol. Oncol.
  doi: 10.1016/j.euo.2018.07.002
– volume: 28
  start-page: 563
  year: 2019
  end-page: 569
  ident: CR36
  article-title: Aspirin and non-aspirin NSAID use and prostate cancer incidence, mortality, and case fatality in the Atherosclerosis Risk in Communities Study
  publication-title: Cancer Epidemiol. Biomarkers Prev.
  doi: 10.1158/1055-9965.EPI-18-0965
– volume: 68
  start-page: 394
  year: 2018
  end-page: 424
  ident: CR1
  article-title: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21492
– volume: 10
  start-page: 410
  year: 2017
  end-page: 420
  ident: CR20
  article-title: Do aspirin and other NSAIDs confer a survival benefit in men diagnosed with prostate cancer? A pooled analysis of NIH-AARP and PLCO cohorts
  publication-title: Cancer Prev. Res. (Phila.)
  doi: 10.1158/1940-6207.CAPR-17-0033
– volume: 10
  start-page: 125
  year: 2010
  end-page: 141
  ident: CR26
  article-title: Low-dose aspirin therapy for cardiovascular prevention: Quantification and consequences of poor compliance or discontinuation
  publication-title: Am. J. Cardiovasc. Drugs
  doi: 10.2165/11318440-000000000-00000
– volume: 11
  start-page: e0152402
  year: 2016
  ident: CR40
  article-title: Aspirin in the treatment of cancer: reductions in metastatic spread and in mortality: A systematic review and meta-analyses of published studies
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0152402
– volume: 19
  start-page: 666
  year: 2017
  end-page: 671
  ident: CR44
  article-title: Effect of statins type on incident prostate cancer risk: A meta-analysis and systematic review
  publication-title: Asian J. Androl.
  doi: 10.4103/1008-682X.168687
– volume: 143
  start-page: 190
  year: 2018
  end-page: 198
  ident: CR43
  article-title: The effect of statin use on the incidence of prostate cancer: A population-based nested case-control study
  publication-title: Int. J. Cancer
  doi: 10.1002/ijc.31295
– volume: 31
  start-page: 3069
  year: 2013
  end-page: 3075
  ident: CR15
  article-title: Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2012.46.7043
– volume: 40
  start-page: 373
  year: 1987
  end-page: 383
  ident: CR34
  article-title: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation
  publication-title: J. Chronic Dis.
  doi: 10.1016/0021-9681(87)90171-8
– volume: 50
  start-page: 303
  year: 2018
  end-page: 316
  ident: CR2
  article-title: Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2015
  publication-title: Cancer Res. Treat.
  doi: 10.4143/crt.2018.143
– volume: 25
  start-page: 154
  year: 2014
  end-page: 159
  ident: CR12
  article-title: A cohort study investigating aspirin use and survival in men with prostate cancer
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdt428
– volume: 20
  start-page: 122
  year: 2017
  end-page: 126
  ident: CR21
  article-title: Metformin and the risk of prostate cancer across racial/ethnic groups: A population-based cohort study
  publication-title: Prostate Cancer Prostatic Dis.
  doi: 10.1038/pcan.2016.65
– volume: 137
  start-page: 2218
  year: 2018
  end-page: 2230
  ident: CR24
  article-title: Prevalence and predictors of cholesterol screening, awareness, and statin treatment among US adults with familial hypercholesterolemia or other forms of severe dyslipidemia (1999–2014)
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.117.032321
– volume: 98
  start-page: 1819
  year: 2006
  end-page: 1825
  ident: CR16
  article-title: Statin drugs and risk of advanced prostate cancer
  publication-title: J. Natl. Cancer Inst.
  doi: 10.1093/jnci/djj499
– volume: 5
  start-page: 1548
  year: 2016
  ident: CR49
  article-title: Diabetes and mortality in patients with prostate cancer: A meta-analysis
  publication-title: Springerplus
  doi: 10.1186/s40064-016-3233-y
– volume: 58
  start-page: 434
  year: 2017
  end-page: 439
  ident: CR54
  article-title: Establishment of Korean prostate cancer database by the Korean Urological Oncology Society
  publication-title: Investig. Clin. Urol.
  doi: 10.4111/icu.2017.58.6.434
– volume: 23
  start-page: 475
  year: 2020
  end-page: 485
  ident: CR45
  article-title: Associations among statins, preventive care, and prostate cancer mortality
  publication-title: Prostate Cancer Prostatic Dis.
  doi: 10.1038/s41391-020-0207-5
– volume: 28
  start-page: 1765
  year: 2019
  end-page: 1768
  ident: CR22
  article-title: Statin use and prostate cancer incidence in Manitoba, Canada: A population-based nested case-control study
  publication-title: Cancer Epidemiol. Biomarkers Prev.
  doi: 10.1158/1055-9965.EPI-19-0464
– volume: 52
  start-page: 335
  year: 2020
  end-page: 350
  ident: CR3
  article-title: Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2017
  publication-title: Cancer Res. Treat.
  doi: 10.4143/crt.2020.206
– volume: 58
  start-page: 434
  year: 2017
  ident: 95764_CR54
  publication-title: Investig. Clin. Urol.
  doi: 10.4111/icu.2017.58.6.434
– volume: 66
  start-page: 1012
  year: 2014
  ident: 95764_CR13
  publication-title: Eur. Urol.
  doi: 10.1016/j.eururo.2014.04.027
– volume: 20
  start-page: 122
  year: 2017
  ident: 95764_CR21
  publication-title: Prostate Cancer Prostatic Dis.
  doi: 10.1038/pcan.2016.65
– volume: 7
  start-page: e33411
  year: 2012
  ident: 95764_CR8
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0033411
– volume: 11
  start-page: e0152402
  year: 2016
  ident: 95764_CR40
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0152402
– volume: 98
  start-page: 1819
  year: 2006
  ident: 95764_CR16
  publication-title: J. Natl. Cancer Inst.
  doi: 10.1093/jnci/djj499
– volume: 7
  start-page: 297
  year: 2013
  ident: 95764_CR39
  publication-title: Ecancermedicalscience
– volume: 52
  start-page: 335
  year: 2020
  ident: 95764_CR3
  publication-title: Cancer Res. Treat.
  doi: 10.4143/crt.2020.206
– volume: 225
  start-page: 184
  year: 2016
  ident: 95764_CR28
  publication-title: Int. J. Cardiol.
  doi: 10.1016/j.ijcard.2016.09.075
– volume: 50
  start-page: 2831
  year: 2014
  ident: 95764_CR14
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2014.08.007
– volume: 38
  start-page: 42
  year: 2014
  ident: 95764_CR17
  publication-title: Cancer Epidemiol.
  doi: 10.1016/j.canep.2013.10.010
– volume: 26
  start-page: 845
  year: 2017
  ident: 95764_CR9
  publication-title: Cancer Epidemiol. Biomarkers Prev.
  doi: 10.1158/1055-9965.EPI-16-1027
– volume: 48
  start-page: 899
  year: 2016
  ident: 95764_CR32
  publication-title: Cancer Res. Treat.
  doi: 10.4143/crt.2015.212
– volume: 28
  start-page: 563
  year: 2019
  ident: 95764_CR36
  publication-title: Cancer Epidemiol. Biomarkers Prev.
  doi: 10.1158/1055-9965.EPI-18-0965
– volume: 4
  start-page: 12
  year: 2015
  ident: 95764_CR23
  publication-title: J. Am. Heart Assoc.
  doi: 10.1161/JAHA.115.002320
– volume: 145
  start-page: 267
  year: 2019
  ident: 95764_CR5
  publication-title: Int. J. Cancer
  doi: 10.1002/ijc.32083
– ident: 95764_CR33
– volume: 35
  start-page: 3290
  year: 2017
  ident: 95764_CR18
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2016.71.8981
– volume: 28
  start-page: 1765
  year: 2019
  ident: 95764_CR22
  publication-title: Cancer Epidemiol. Biomarkers Prev.
  doi: 10.1158/1055-9965.EPI-19-0464
– volume: 23
  start-page: 475
  year: 2020
  ident: 95764_CR45
  publication-title: Prostate Cancer Prostatic Dis.
  doi: 10.1038/s41391-020-0207-5
– volume: 76
  start-page: 469
  year: 2016
  ident: 95764_CR42
  publication-title: Prostate
  doi: 10.1002/pros.23138
– volume: 8
  start-page: 1055
  year: 2015
  ident: 95764_CR48
  publication-title: Cancer Prev. Res. (Phila.)
  doi: 10.1158/1940-6207.CAPR-15-0141
– volume: 19
  start-page: 666
  year: 2017
  ident: 95764_CR44
  publication-title: Asian J. Androl.
  doi: 10.4103/1008-682X.168687
– volume: 22
  start-page: 1877
  year: 2013
  ident: 95764_CR30
  publication-title: Cancer Epidemiol. Biomarkers Prev.
  doi: 10.1158/1055-9965.EPI-13-0196
– volume: 63
  start-page: 709
  year: 2013
  ident: 95764_CR53
  publication-title: Eur. Urol.
  doi: 10.1016/j.eururo.2012.12.004
– volume: 170
  start-page: 443
  year: 2019
  ident: 95764_CR11
  publication-title: Ann. Intern. Med.
  doi: 10.7326/M17-3085
– volume: 113
  start-page: 403
  year: 2015
  ident: 95764_CR31
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.2015.259
– volume: 2
  start-page: 126
  year: 2019
  ident: 95764_CR10
  publication-title: Eur. Urol. Oncol.
  doi: 10.1016/j.euo.2018.07.002
– volume: 10
  start-page: 625
  year: 2013
  ident: 95764_CR4
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/nrclinonc.2013.169
– volume: 113
  start-page: 845
  year: 2018
  ident: 95764_CR29
  publication-title: Am. J. Gastroenterol.
  doi: 10.14309/00000434-201806000-00015
– volume: 71
  start-page: 5754
  year: 2011
  ident: 95764_CR51
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-10-2470
– volume: 137
  start-page: 2218
  year: 2018
  ident: 95764_CR24
  publication-title: Circulation
  doi: 10.1161/CIRCULATIONAHA.117.032321
– volume: 10
  start-page: 410
  year: 2017
  ident: 95764_CR20
  publication-title: Cancer Prev. Res. (Phila.)
  doi: 10.1158/1940-6207.CAPR-17-0033
– volume: 84
  start-page: e13
  year: 2012
  ident: 95764_CR37
  publication-title: Int. J. Radiat. Oncol. Biol. Phys.
  doi: 10.1016/j.ijrobp.2012.02.050
– volume: 31
  start-page: 3069
  year: 2013
  ident: 95764_CR15
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2012.46.7043
– volume: 3
  start-page: 212
  year: 2017
  ident: 95764_CR19
  publication-title: Eur. Urol. Focus
  doi: 10.1016/j.euf.2016.05.004
– volume: 40
  start-page: 373
  year: 1987
  ident: 95764_CR34
  publication-title: J. Chronic Dis.
  doi: 10.1016/0021-9681(87)90171-8
– volume: 75
  start-page: 1384
  year: 2015
  ident: 95764_CR46
  publication-title: Prostate
  doi: 10.1002/pros.23019
– volume: 68
  start-page: 394
  year: 2018
  ident: 95764_CR1
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21492
– volume: 62
  start-page: 76
  year: 2008
  ident: 95764_CR27
  publication-title: Int. J. Clin. Pract.
  doi: 10.1111/j.1742-1241.2007.01630.x
– volume: 10
  start-page: 13715
  year: 2020
  ident: 95764_CR35
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-020-70624-8
– volume: 116
  start-page: 1820
  year: 2010
  ident: 95764_CR38
  publication-title: Cancer
  doi: 10.1002/cncr.24890
– volume: 16
  start-page: 789
  year: 2005
  ident: 95764_CR52
  publication-title: Cancer Causes Control
  doi: 10.1007/s10552-005-3301-z
– volume: 50
  start-page: 303
  year: 2018
  ident: 95764_CR2
  publication-title: Cancer Res. Treat.
  doi: 10.4143/crt.2018.143
– volume: 31
  start-page: 336
  year: 2015
  ident: 95764_CR50
  publication-title: Diabetes Metab Res. Rev.
  doi: 10.1002/dmrr.2582
– volume: 143
  start-page: 190
  year: 2018
  ident: 95764_CR43
  publication-title: Int. J. Cancer
  doi: 10.1002/ijc.31295
– volume: 5
  start-page: 930
  year: 2005
  ident: 95764_CR7
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc1751
– volume: 23
  start-page: 1277
  year: 2003
  ident: 95764_CR41
  publication-title: Int. J. Oncol.
– volume: 25
  start-page: 154
  year: 2014
  ident: 95764_CR12
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdt428
– volume: 2
  start-page: 762
  year: 2016
  ident: 95764_CR6
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2015.6396
– volume: 8
  start-page: 381
  year: 2016
  ident: 95764_CR25
  publication-title: Clin. Epidemiol.
  doi: 10.2147/CLEP.S113211
– volume: 5
  start-page: 1548
  year: 2016
  ident: 95764_CR49
  publication-title: Springerplus
  doi: 10.1186/s40064-016-3233-y
– volume: 9
  start-page: e116327
  year: 2014
  ident: 95764_CR47
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0116327
– volume: 10
  start-page: 125
  year: 2010
  ident: 95764_CR26
  publication-title: Am. J. Cardiovasc. Drugs
  doi: 10.2165/11318440-000000000-00000
SSID ssj0000529419
Score 2.389072
Snippet We evaluated the association between aspirin, statins, and metformin use and prostate cancer (PC) incidence and mortality using a large population-based...
Abstract We evaluated the association between aspirin, statins, and metformin use and prostate cancer (PC) incidence and mortality using a large...
SourceID doaj
pubmedcentral
proquest
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
Publisher
StartPage 16171
SubjectTerms 692/308/174
692/699/67
692/699/67/2195
692/699/67/2324
692/699/67/589
692/699/67/589/466
Antidiabetics
Aspirin
Diabetes mellitus
Drug dosages
Humanities and Social Sciences
Medical screening
Metformin
Mortality
multidisciplinary
Prostate cancer
Science
Science (multidisciplinary)
Statins
SummonAdditionalLinks – databaseName: DOAJ (Directory of Open Access Journals)
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Ni9UwEA-yIHgR1w-srhLBm6_s5qNJc1zFZREUDy7sLeSrWNC8Zfse4n_vTNL33C6oF0-FZkKbzKTzSyfzG0JeI8UIM463vutUK_vQtc5p2ZrYeWU8ODSPyckfP6nzC_nhsru8UeoLz4RVeuA6cccpmN7LE2FSkgCVo5M8ahXBzQ89c2bAry_4vBubqcrqzY1kZs6SORH98QSeCrPJ8EQCYGzZioUnKoT9C5R5-4zkrUBp8T9nD8j9GTjS0_rCh-ROyg_J3VpK8ucjMn7eV-Jqf4wx0Zr-ONH1QB1G08e8opg9NOZpRV2O9HvaIGAdM91Oia4zvcIEEICeNKAlXFP8C18qjlbxgtMBsz8mF2fvv7w7b-cyCm3omN60SiDrm_BSyeC08cw5F2FpexZ6Dnrx3isXOz2Ab-9F9CaAS2dapKBTjHwQT8hBXuf0lNAkDUZWmeg87rUSgF0DV-4GF5gcREPYbkptmDnGsdTFN1ti3aK3VQ0W1GCLGiz0ebPvc1UZNv4q_RY1tZdEduxyA2zGzjZj_2UzDTna6dnOS3ayuLcC-Co5b8irfTMsNoyguJzWW5RRmL0rtW6IXtjH4oWWLXn8Wmi7Eev2RjVktbOk3w__84Cf_Y8BPyf3OFp-OepyRA4219v0AsDUxr8s6-YXAiYbRA
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Ni9QwFA-6IngRP7G6SgRvTthNkybNSVRcFkHx4MLcQr6qBTcdpzOI_715aaZLF9xToUlo2vde3q_vE6E3UGKEKlMT2zSC8NY1xBjJifKNFcomhWYhOfnLV3F-wT-vm3UxuI0lrPJwJuaD2g8ObOQnAH0TuuB1_W7zm0DXKPCulhYat9EdKF0GIV1yLWcbC3ixOFUlV-aUtSdj0leQUwZxCQlpc8IW-iiX7V9gzeuRktfcpVkLnT1A9wt8xO8nej9Et0J8hO5ODSX_Pkb9t7kfF_nT-4CnJMgRDx024FPv4wpDDlEfxxU20ePLsAPY2ke8HwMeIt5AGkgCoNgBP2wx2OJz39FpekbrCbk_QRdnn75_PCelmQJxDZU7IhjUfmOWC-6MVJYaY3wScEtdWyfqWGuF8Y3skoZvmbfKJcVOJQtOBu_rjj1FR3GI4RnCgSvwr1LWWPjjCgnyqnStTWcc5R2rED18Uu1KpXFoePFLZ483a_VEBp3IoDMZdFrzdl6zmeps3Dj7A1Bqngk1svONYftDF5HTwanW8lOmQuBpe97w2kvhE0DsWmpUV6HjA511EdxRX7FZhV7Pw0nkwI9iYhj2MEdADi-XskJywR-LDS1HYv8zF-8GxNsqUaHVgZOuHv7_F35-815foHs18HQOZTlGR7vtPrxMYGlnX2WJ-AffyhKP
  priority: 102
  providerName: ProQuest
– databaseName: Springer Nature OA Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bi9UwEA7riuCLeMXqKhF88wQ3lybNox5cFkHxwYV9C7lVC5oup-cg_nsz6UW6qOBToZ3QtDPpfOnMfIPQS6AYodoy4upaEtH4mlirBNGhdlK77NAcFCd_-CjPL8T7y_ryCLG5FqYk7RdKy_KZnrPDXg_Z0UAxGCQUZIgsCL-BbgJ1O1j1Vm6X_yoQuRJUT_Uxp7z5w9CVDypU_St8eT078lqItHies7vozgQZ8ZtxkvfQUUz30a2xieTPB6j7tPTgIj-6EPFY-DjgvsUW4uhd2mCoG-rSsME2Bfw97gGqdgkfhoj7hK-g9CODTuzBBnYY_r-XXqOjeEHoGa0_RBdn7z5vz8nUQIH4mqo9kRz43rgTUnirtKPW2pAXtaO-YVkjzjlpQ63a7NUbHpz22ZlTxaNXMQTW8kfoOPUpPkY4Cg0xVcprB7usmGGuzkdmW-upaHmF6PxKjZ_YxaHJxTdToty8MaMaTFaDKWowecyrZczVyK3xT-m3oKlFEnixy4l-98VMdmKi140Tp1zHKPL0ghUsKBkyKGwbanVboZNZz2ZarIOBXVUGroKxCr1YLudlBrETm2J_ABkJdbtCqQqplX2sJrS-krqvhbAbUG6jZYU2syX9vvnfH_jJ_4k_RbcZ2HhJZzlBx_vdIT7LgGnvnpcV8guIzRB3
  priority: 102
  providerName: Springer Nature
Title Population-wide impacts of aspirin, statins, and metformin use on prostate cancer incidence and mortality
URI https://link.springer.com/article/10.1038/s41598-021-95764-3
https://www.proquest.com/docview/2559540422
https://www.proquest.com/docview/2560057477
https://pubmed.ncbi.nlm.nih.gov/PMC8352896
https://doaj.org/article/ec98b4039ee4428da42d76d143f81a9f
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3da9swEBf9YLCXsU_mtQsa7G3RNtuyZD2MkYaWEmgp2wJ5M_pyZ-jsNk7Y-t_vTrYzUrqxJ4Et2bLujvvJp_sdIW-RYiRWOmEmywTjuc2Y1pIz5TIjlAGHZjA5-excnM75bJEtdshQ7qhfwPberR3Wk5ovr97_urn9DAb_qUsZzz-04IQwUQwPGwB85izdJfvgmSQa6lkP9zuu70TxUOsDSdgZgImkz6O5_zFbvipQ-m_h0LunKO-EUoOHOnlMHvXQkk46XXhCdnz9lDzoik3ePiPVxaZWF_tZOU-7BMmWNiXVGG-v6jHF_KKqbsdU147-8CuEtFVN162nTU2vMUUEwCm1qCtLiv_pQ03SrntYRED1z8n85Pjb9JT1hRaYzWK5YiJFXrjUcMGtlsrEWmsHxm9imycgOWOM0C6TJXj_PHVGWXD6sUy9ld65pExfkL26qf1LQj1XGHuN08zgbswDHFbQJrrUNuZlGpF4WNLC9izkWAzjqgjR8DQvOjEUIIYiiKGAMe82Y647Do5_9j5CSW16In92uNAsL4veHAtvVW74x1R5z2F6TvPESeEAPJZ5rFUZkcNBzsWgkwXuvgDg8iSJyJvNbTBHjLHo2jdr7CMwv5dLGRG5pR9bE9q-U1ffA7E3ouFciYiMB0368_K_f_Cr_5jMAXmYoGKHsy6HZG-1XPvXgKZWZkR25UKOyP5kMvs6g_bo-PziC1ydiuko_KEYBSP6DY-4H4g
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrRC9IJ7qQgEjwYmN2sTOwweEKLTa0nZVoVbqzfgViFSSZbOrqn-K38hMHlttJXrrKVJiJxPP2PONxzMD8I5SjIRSR4GJ4yQQmY0DrVMRSBebRBpUaIaCk48nyfhMfDuPz9fgbx8LQ8cq-zWxWahdZWmPfJugL6ILEUWfpn8CqhpF3tW-hEYrFof-6hJNtvrjwVfk7_so2t87_TIOuqoCgY3DdB4knJKgcSMSYXUqTai1dijpJrRZhGQaYxLt4jRHVZdxZ6RFDRem3NvUOxflHN97D9YFR1NmAOu7e5OT78tdHfKbiVB20Tk7PNuuUUNSFBudhEBsLwK-ogGbQgEr6Pbm2cwbDtpG7-0_gocdYGWfWwl7DGu-fAL32xKWV0-hOFlWAAsuC-dZG3ZZsypnmrz4RTliFLVUlPWI6dKx335OQLko2aL2rCrZlAJPEPIySxI4Y7T731Q6bZs39gHaCs_g7E4G-jkMyqr0m8C8kOTRDXlsyMbzCLIlXiOdaxuKnA8h7IdU2S63OZXYuFCNj51nqmWDQjaohg0K-3xY9pm2mT1ubb1LnFq2pKzczY1q9lN1k1x5KzMjdrj0XiB5TovIpYlDSJpnoZb5ELZ6PqtuqajVtWAP4e3yMU5y8tzo0lcLapNQ1LBI0yGkK_KxQtDqk7L41aQLJ4ydyWQIo16Srj_-_x9-cTutb-DB-PT4SB0dTA5fwkZE8t0cpNmCwXy28K8Qqs3N625-MPhx11PyHz4SUUI
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKEYgL4qkuFDASnNho69iJ4wNCQFm1FKoeqLQ341cgEiTLZldV_xq_jhkn2Wor0VtPkRI7cTwzns-eFyGvMMUIUyZNbJbliShclhgjRaJ8ZnNlQaFZDE7-epwfnIrPs2y2Rf4OsTDoVjmsiXGh9o3DM_IJQl9AFyJNJ2XvFnGyP303_5NgBSm0tA7lNDoWOQrnZ7B9a98e7gOtX6fp9NO3jwdJX2EgcRmTyyTnmBCNW5ELZ6SyzBjjgestc0UKQ7bW5sZnsgS1V3BvlQNtxyQPTgbv05LDe2-Qm5JnDGVMzuT6fActaIKpPk5njxeTFnQlxrOhTwSgfJHwDV0YSwZs4NzLXpqXTLVRA07vkbs9dKXvO167T7ZC_YDc6opZnj8k1cm6FlhyVvlAuwDMljYlNWjPr-oxxfilqm7H1NSe_g5LhMxVTVdtoE1N5xiCAuCXOuTFBUU7QKx52jWPOwXYNTwip9cyzY_Jdt3UYYfQIBTadhnPLO72AsBtBdfUlMYxUfIRYcOUatdnOcdiG790tLbzQndk0EAGHcmgoc-bdZ95l-PjytYfkFLrlpifO95oFj90L-46OFVYscdVCAKG541Ivcw9gNOyYEaVI7I70Fn3i0arL1h8RF6uH4O4ow3H1KFZYZsc44eFlCMiN_hjY0CbT-rqZ0wcjmi7UPmIjAdOuvj4_3_4ydVjfUFugyDqL4fHR0_JnRTZO3rU7JLt5WIVngFmW9rnUTgo-X7d0vgPK5ZUEg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Population-wide+impacts+of+aspirin%2C+statins%2C+and+metformin+use+on+prostate+cancer+incidence+and+mortality&rft.jtitle=Scientific+reports&rft.au=Koo%2C+Hye+Yeon&rft.au=Jeong%2C+Su-Min&rft.au=Cho%2C+Mi+Hee&rft.au=Chun%2C+Sohyun&rft.date=2021-08-09&rft.issn=2045-2322&rft.eissn=2045-2322&rft.volume=11&rft.issue=1&rft.spage=16171&rft_id=info:doi/10.1038%2Fs41598-021-95764-3&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon